

Table 1. Clinical trials of oncolytic herpes simplex virus 1 virotherapy in glioma

Viruses	Phase	Patients	Trial	Identifier
G207	Phase 1	Recurrent malignant glioma	G207	Markert JM, 2000 (6)
	Phase 1b/2	Recurrent GBM	G207	NCT00028158
	Phase 1b	Recurrent malignant glioma	Two inoculations of G207	Markert JM, 2009 (5)
	Phase 1	Recurrent malignant glioma	G207 and a single radiation	NCT00157703 (7)
	Phase 1	Progressive or recurrent malignant glioma in children	G207 alone or with a single radiation	NCT02457845 (3, 11)
	Phase 1	Recurrent of refractory cerebellar brain tumor in children	G207 alone or with a single radiation	NCT03911388 (1)
	Phase 2	Recurrent malignant glioma in children	G207 with a single radiation	NCT04482933
G47Δ	Phase 1/2a	Recurrent malignant glioma	G47Δ	UMIN000002661
	Phase 2	Recurrent malignant glioma	G47Δ	UMIN000015995 (10)
rQNestin34.5v.2	Phase 1	Recurrent malignant glioma	Arm A: rQNestin Arm B: rQNestin + Cyclophosphamide	NCT03152318 (2)
M032	Phase 1	Recurrent malignant glioma	M032	NCT02062827
C134	Phase 1	Recurrent malignant glioma	C134	NCT03657576
HSV-1716	Phase 1	Recurrent malignant glioma	HSV 1716	Rampling R, 2000 (9)
	Phase 1	Newly or recurrent malignant glioma	HSV 1716	Papanastassiou V, 2002 (8)
	Phase 1	Newly or recurrent malignant glioma	HSV 1716 and maximal resection	Harrow S, 2004 (4)
	Phase 1	Refractory or recurrent malignant glioma in child	HSV-1716 and dexamethasone	NCT02031965

1. Bernstock JD, Bag AK, Fiveash J, et al. (2020) Design and rationale for first-in-human phase 1 immunovirotherapy clinical trial of oncolytic HSV G207 to treat malignant pediatric cerebellar brain tumors. *Hum Gene Ther* 31(19-20):1132-1139
2. Chiocca EA, Solomon I, Nakashima H, et al. (2021) First-in-human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma. *Journal of Clinical Oncology* 39(15_suppl):2009-2009
3. Friedman GK, Johnston JM, Bag AK, et al. (2021) Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. *N Engl J Med* 384(17):1613-1622
4. Harrow S, Papanastassiou V, Harland J, et al. (2004) HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. *Gene Ther* 11(22):1648-1658
5. Markert JM, Liechty PG, Wang W, et al. (2009) Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. *Mol Ther* 17(1):199-207
6. Markert JM, Medlock MD, Rabkin SD, et al. (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. *Gene Ther* 7(10):867-874
7. Markert JM, Razdan SN, Kuo HC, et al. (2014) A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. *Mol Ther* 22(5):1048-1055
8. Papanastassiou V, Rampling R, Fraser M, et al. (2002) The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. *Gene Ther* 9(6):398-406
9. Rampling R, Cruickshank G, Papanastassiou V, et al. (2000) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. *Gene Ther* 7(10):859-866
10. Todo T (2019) ATIM-14. Results of phase ii clinical trial of oncolytic herpes virus G47 δ in patients with glioblastoma. *Neuro-Oncology* 21(Suppl 6):vi4-vi4
11. Waters AM, Johnston JM, Reddy AT, et al. (2017) Rationale and design of a phase 1 clinical trial to evaluate HSV G207 alone or with a single radiation dose in children with progressive or recurrent malignant supratentorial brain tumors. *Hum Gene Ther Clin Dev* 28(1):7-16